| Literature DB >> 28485313 |
Shu-Bin Guo1, Yun-Xia Chen1, Xue-Zhong Yu2.
Abstract
BACKGROUND: Shock is a life-threatening condition in emergency departments (EDs) and is associated with a high mortality; however, its clinical characteristics and current interventions in China are seldom reported. This study investigated the clinical characteristics and current interventions of shock patients in Chinese EDs.Entities:
Mesh:
Year: 2017 PMID: 28485313 PMCID: PMC5443019 DOI: 10.4103/0366-6999.205862
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Figure 1Flowchart of the screening and enrollment of the patients.
Characteristics of enrolled shock patients
| Parameters | Whole cohort ( | Septic shock ( | Hemorrhagic and traumatic shock ( | Cardiogenic shock ( | Neurogenic shock ( | Anaphylactic shock ( | Burn shock ( |
|---|---|---|---|---|---|---|---|
| Age (years) | 59 ± 19 | 64 ± 18 | 52 ± 18 | 65 ± 18 | 56 ± 16 | 52 ± 20 | 49 ± 15 |
| Male, | 688 (62.8) | 267 (60.4) | 296 (69.2) | 93 (55.4) | 17 (60.7) | 7 (46.7) | 8 (57.1) |
| Comorbidities and past medical history, | |||||||
| CVD | 143 (13.1) | 66 (14.9) | 24 (5.6) | 49 (29.2) | 3 (10.7) | 1 (6.7) | 0 |
| Arrhythmia | 70 (6.4) | 38 (8.6) | 5 (1.2) | 27 (16.1) | 0 | 0 | 0 |
| Hypertension | 342 (31.2) | 154 (34.8) | 99 (23.1) | 69 (41.1) | 10 (35.7) | 6 (40.0) | 4 (28.6) |
| CHF | 59 (5.4) | 32 (7.2) | 7 (1.6) | 19 (11.3) | 1 (3.6) | 0 | 0 |
| Hyperlipidemia | 27 (2.5) | 12 (2.7) | 6 (1.4) | 8 (4.8) | 1 (3.6) | 0 | 0 |
| Diabetes mellitus | 156 (14.2) | 73 (16.5) | 44 (10.3) | 35 (20.8) | 2 (7.1) | 2 (13.3) | 0 |
| Cerebral hemorrhage | 25 (2.3) | 18 (4.1) | 3 (0.7) | 2 (1.2) | 2 (7.1) | 0 | 0 |
| Cerebral infarction | 62 (5.7) | 37 (8.4) | 14 (3.3) | 9 (5.4) | 1 (3.6) | 1 (6.7) | 0 |
| Tumor | 78 (7.1) | 44 (10.0) | 25 (5.8) | 6 (3.6) | 1 (3.6) | 2 (13.3) | 0 |
| Cholelithiasis | 25 (2.3) | 19 (4.3) | 4 (0.9) | 1 (0.6) | 1 (3.6) | 0 | 0 |
| Urinary calculus | 16 (1.5) | 12 (2.7) | 1 (0.2) | 1 (0.6) | 2 (7.1) | 0 | 0 |
| Surgery | 128 (11.7) | 74 (16.7) | 31 (7.2) | 17 (10.1) | 3 (10.7) | 3 (20.0) | 0 |
| Allergy | 30 (2.7) | 16 (3.6) | 7 (1.6) | 3 (1.8) | 1 (3.6) | 3 (20.0) | 0 |
| Healthy | 365 (33.3) | 101 (22.9) | 199 (46.5) | 39 (23.2) | 11 (39.3) | 5 (33.5) | 10 (71.4) |
| Armpit temperature (°C) | 36.7 (36.1–37.5) | 37.0 (36.3–38.4) | 36.5 (36.0–37.0) | 36.5 (36.0–37.0) | 36.5 (35.8–37.8) | 36.5 (36.5–37.0) | 36.2 (36.0–37.2) |
| Heart rate (beats/min) | 110 (95–125) | 111 (99–126) | 110 (100–124) | 107 (84–128) | 70 (61–75) | 109 (91–128) | 115 (107–120) |
| Respiratory rate (beats/min) | 22 (19–25) | 23 (20–28) | 21 (19–24) | 21 (18–26) | 20 (17–22) | 20 (19–24) | 23 (20–28) |
| SBP (mmHg) | 78 (71–85) | 78 (70–85) | 79 (73–86) | 78 (70–87) | 76 (67–89) | 80 (79–87) | 85 (74–91) |
| DBP (mmHg) | 48 (40–55) | 46 (40–54) | 50 (41–56) | 49 (40–56) | 49 (40–56) | 57 (43–68) | 51 (47–56) |
| MAP (mmHg) | 58 (52–65) | 57 (51–63) | 60 (52–65) | 59 (50–65) | 59 (49–67) | 67 (53–73) | 63 (53–67) |
| SpO2 (%) | 94 (87–97) | 93 (85–97) | 95 (90–98) | 90 (83–96) | 91 (85–99) | 95 (85–98) | 96 (94–98) |
| MEWS | 5 (4–7) | 5 (4–7) | 5 (4–6) | 5 (4–6) | 4 (3–5) | 4 (3–5) | 5 (4–6) |
Data were shown as mean ± SD, n (%) or median (quartile). CVD: Cardiovascular disease; CHF: Chronic heart failure; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MAP: Mean arterial pressure; SpO2: Transcutaneous oxygen saturation; MEWS: Modified Early Warning Score; SD: Standard deviation.
Interventions, treatments, and outcomes of the study cohort (n (%))
| Interventions | Whole cohort ( | Septic shock ( | Hemorrhagic and traumatic shock ( | Cardiogenic shock ( | Neurogenic shock ( | Anaphylactic shock ( | Burn shock ( |
|---|---|---|---|---|---|---|---|
| Antibiotics | 638 (58.3) | 420 (95.0) | 147 (34.3) | 52 (31.0) | 13 (46.4) | 1 (6.7) | 5 (35.7) |
| Glucocorticoid | 177 (16.2) | 86 (19.5) | 67 (15.7) | 9 (5.4) | 5 (17.9) | 5 (33.3) | 5 (35.7) |
| Ulinastatin | 121 (11.1) | 89 (20.1) | 22 (5.1) | 5 (3.0) | 4 (14.3) | 0 | 1 (7.1) |
| Glucose control | 154 (14.1) | 76 (17.2) | 47 (11.0) | 23 (13.7) | 5 (17.9) | 1 (6.7) | 2 (14.3) |
| Hemodynamic monitoring | 629 (57.4) | 271 (61.3) | 223 (52.1) | 105 (62.5) | 17 (60.7) | 11 (73.3) | 2 (14.3) |
| Bicarbonate | 257 (23.5) | 119 (26.9) | 76 (17.8) | 57 (33.9) | 4 (14.3) | 0 | 1 (7.1) |
| Proton pump inhibitor | 549 (50.1) | 240 (54.3) | 223 (52.1) | 65 (38.7) | 15 (53.6) | 1 (6.7) | 5 (35.7) |
| Red blood transfusion | 352 (32.1) | 56 (12.7) | 279 (65.2) | 6 (3.6) | 3 (10.7) | 0 | 8 (57.1) |
| Anti-allergy | 23 (2.1) | 5 (1.1) | 5 (1.2) | 1 (0.6) | 0 | 12 (80.0) | 0 |
| Emergency surgery | 118 (10.8) | 18 (4.1) | 83 (19.4) | 12 (7.1) | 2 (7.1) | 0 | 3 (21.4) |
| Resuscitation fluids | 1033 (94.3) | 422 (95.5) | 418 (97.7) | 143 (85.1) | 24 (85.7) | 12 (80.0) | 14 (100) |
| Colloids | 505 (46.1) | 214 (48.4) | 231 (54.0) | 38 (22.6) | 12 (42.9) | 4 (26.7) | 6 (42.9) |
| Albumin | 152 (13.9) | 88 (19.9) | 44 (10.3) | 15 (8.9) | 3 (10.7) | 0 | 2 (14.3) |
| Dextran | 71 (6.5) | 26 (5.9) | 33 (7.7) | 9 (5.4) | 1 (3.6) | 2 (13.3) | 0 |
| Hydroxyethyl starch | 324 (29.6) | 131 (29.6) | 161 (37.6) | 15 (8.9) | 10 (35.7) | 2 (13.3) | 5 (35.7) |
| Succinylated gelatin | 61 (5.6) | 14 (3.2) | 40 (9.3) | 7 (4.2) | 0 | 0 | 0 |
| Crystalloids | 992 (90.6) | 409 (92.5) | 403 (94.2) | 133 (79.2) | 23 (82.1) | 10 (66.7) | 14 (100) |
| 0.9% saline | 963 (87.9) | 401 (90.7) | 389 (90.9) | 130 (77.4) | 22 (78.6) | 10 (66.7) | 11 (78.6) |
| Ringer’s lactate | 525 (47.9) | 203 (45.9) | 254 (59.3) | 47 (28.0) | 7 (25.0) | 1 (6.7) | 13 (92.9) |
| Vascular active agents | 704 (64.3) | 322 (72.9) | 207 (48.4) | 142 (84.5) | 21 (75.0) | 8 (53.3) | 4 (28.6) |
| Vasopressors | 701 (64.0) | 319 (72.2) | 207 (48.4) | 142 (84.5) | 21 (75.0) | 8 (53.3) | 4 (28.6) |
| Norepinephrine | 282 (25.8) | 150 (33.9) | 85 (19.9) | 39 (23.2) | 5 (17.9) | 0 | 3 (21.4) |
| Epinephrine | 182 (16.6) | 55 (12.4) | 61 (14.3) | 55 (32.7) | 5 (17.9) | 6 (40.0) | 0 |
| Dopamine | 505 (46.1) | 234 (52.9) | 142 (33.2) | 106 (63.1) | 18 (64.3) | 2 (13.3) | 3 (21.4) |
| Dobutamine | 30 (2.7) | 13 (2.9) | 4 (0.9) | 13 (7.7) | 0 | 0 | 0 |
| Organ function support | |||||||
| Mechanical ventilation | 358 (32.7) | 166 (37.6) | 98 (22.9) | 79 (47.0) | 12 (42.9) | 0 | 3 (21.4) |
| CRRT | 40 (3.7) | 27 (6.1) | 5 (1.2) | 6 (3.6) | 2 (7.1) | 0 | 0 |
| Outcomes | |||||||
| ICU admission | 1039 (94.9) | 422 (95.5) | 408 (95.3) | 155 (92.3) | 27 (96.4) | 13 (86.7) | 14 (100.0) |
| 3-day mortality | 301 (27.5) | 128 (29.0) | 104 (24.3) | 61 (36.3) | 6 (21.4) | 0 | 2 (14.3) |
CRRT: Continuous renal replacement therapy; ICU: Intensive Care Unit.
Risk factors of mortality
| Risk factors | 3-day mortality | ||||
|---|---|---|---|---|---|
| With risk factor (%) | Without risk factor (%) | ||||
| The whole cohort ( | |||||
| Cardiogenic shock | 36.3 | 25.9 | 1.40 | 7.747 | 0.005 |
| Anaphylactic shock | 0 | 27.9 | 5.765 | 0.016 | |
| Tumor | 42.3 | 26.4 | 1.60 | 9.253 | 0.002 |
| MEWS >5 | 33.1 | 23.6 | 1.40 | 12.116 | <0.001 |
| Bicarbonate | 42.0 | 23.0 | 1.83 | 35.593 | <0.001 |
| Red blood transfusion | 22.4 | 29.9 | 0.75 | 6.625 | 0.010 |
| Emergency surgery | 14.4 | 29.1 | 0.49 | 11.36 | 0.001 |
| HES | 32.1 | 25.6 | 1.25 | 4.907 | 0.027 |
| Ringer’s lactate | 21.1 | 33.3 | 0.63 | 20.375 | <0.001 |
| Second-choice vasopressor | 39.2 | 15.1 | 2.60 | 79.818 | <0.001 |
| Mechanical ventilation | 37.7 | 22.5 | 1.68 | 27.877 | <0.001 |
| Septic shock ( | |||||
| CVD | 18.2 | 30.9 | 0.59 | 4.380 | 0.036 |
| Cerebral hemorrhage | 5.6 | 30.0 | 0.19 | 4.996 | 0.025 |
| Tumor | 47.7 | 26.9 | 1.77 | 8.366 | 0.004 |
| Antibiotics | 27.9 | 50.0 | 0.56 | 4.982 | 0.026 |
| Bicarbonate | 43.7 | 23.5 | 1.86 | 17.193 | <0.001 |
| HES | 38.2 | 25.1 | 1.52 | 7.674 | 0.006 |
| Ringer’s lactate | 18.7 | 37.7 | 0.50 | 19.135 | <0.001 |
| Second-choice vasopressor | 39.0 | 15.7 | 2.48 | 28.713 | <0.001 |
| Hemorrhagic and traumatic shock ( | |||||
| MEWS >5 | 33.8 | 19.0 | 1.78 | 11.721 | 0.001 |
| Bicarbonate | 35.5 | 21.9 | 1.62 | 6.332 | 0.012 |
| Red blood transfusion | 18.6 | 34.9 | 0.53 | 13.963 | <0.001 |
| Emergency surgery | 12.0 | 27.2 | 0.44 | 8.401 | 0.004 |
| Norepinephrine | 32.9 | 22.2 | 1.48 | 4.306 | 0.038 |
| Second-choice vasopressor | 41.2 | 14.2 | 2.90 | 39.914 | <0.001 |
| Mechanical ventilation | 44.9 | 18.2 | 2.47 | 29.319 | <0.001 |
| Cardiogenic shock ( | |||||
| Glucose control | 60.9 | 32.4 | 1.88 | 6.951 | 0.008 |
| Diabetes mellitus ( | 50.0 | 44.0 | 1.14 | 0.104 | >0.05 |
| Nondiabetic ( | 69.2 | 30.0 | 2.31 | 8.064 | 0.01 |
| Bicarbonate | 47.7 | 30.6 | 1.56 | 4.562 | 0.033 |
| Second-choice vasopressor | 42.3 | 20.0 | 2.12 | 7.070 | 0.008 |
Second-choice vasopressors: Any of epinephrine and dopamine. RR: Relative risk; MEWS: Modified Early Warning Score; CVD: Cardiovascular disease; HES: Hydroxyethyl starch.
The independent predictors of 3-day mortality
| Independent predictors | SE | Wald | 95% | ||||
|---|---|---|---|---|---|---|---|
| 5% | 95% | ||||||
| The whole cohort | |||||||
| Tumor | 0.618 | 0.255 | 5.890 | 0.015 | 1.855 | 1.126 | 3.055 |
| Bicarbonate | 0.606 | 0.160 | 14.259 | <0.001 | 7.832 | 1.338 | 2.509 |
| Ringer’s lactate | −0.482 | 0.146 | 10.970 | 0.001 | 0.617 | 0.464 | 0.821 |
| Second-choice vasopressor | 1.103 | 0.154 | 51.072 | <0.001 | 3.014 | 2.227 | 4.079 |
| Constant | −1.616 | 0.144 | 125.361 | <0.001 | 0.199 | ||
| Septic shock | |||||||
| Ringer’s lactate | −1.005 | 0.232 | 18.806 | <0.001 | 0.366 | 0.232 | 0.576 |
| Second-choice vasopressor | 1.269 | 0.243 | 27.373 | <0.001 | 3.557 | 2.211 | 5.723 |
| Constant | −1.291 | 0.214 | 36.493 | <0.001 | 0.275 | ||
| Hemorrhagic and traumatic shock | |||||||
| MEWS >5 | 0.679 | 0.249 | 7.428 | 0.006 | 1.971 | 1.210 | 3.212 |
| Red blood transfusion | −0.982 | 0.904 | 0.007 | <0.001 | 0.374 | 0.230 | 0.611 |
| Second-choice vasopressor | 1.389 | 0.247 | 31.681 | <0.001 | 4.012 | 2.473 | 6.508 |
| Constant | −1.461 | 0.231 | 39.848 | <0.001 | 0.232 | ||
| Cardiogenic shock | |||||||
| Glucose control | 1.171 | 0.474 | 6.099 | 0.014 | 3.226 | 1.273 | 8.171 |
| Second-choice vasopressor | 1.071 | 0.423 | 6.417 | 0.011 | 2.917 | 1.274 | 6.679 |
| Constant | −1.555 | 0.388 | 16.085 | <0.001 | 0.211 | ||
Second-choice vasopressors: Any of epinephrine and dopamine. SE: Standard error; OR: Odds ratio; CI: Confidence interval; MEWS: Modified Early Warning Score.